TON - November 2016, Vol 9, No 6

SGX942, a novel agent that is first in its class, decreased the incidence of severe oral mucositis in patients with head and neck cancer undergoing chemoradiation, according to new research.

Women with clinicopathologic high-risk breast cancer had nearly a 50% reduction in prescription chemotherapy, with no increased risk for metastatic recurrence when a cancer gene–based assay was used to guide treatment decision­-making, according to new data presented at the 2016 American Association for Cancer Research meeting.

In the United States, the 3.1 million registered nurses (RNs) account for the largest health profession, and this is projected to grow by 33% by 2025 (from 2012).
It is well-recognized that radiation-induced symptoms can be extremely severe for patients with head and neck cancer. Although “magic mouthwash” (ie, diphenhydramine plus lidocaine plus antacid [DLA]) is frequently used for the treatment of oral mucositis associated with radiotherapy to the head and neck, until now there has been no solid evidence for this approach.
Hypofractionated radiotherapy achieves comparable quality of life compared with conventional radiotherapy, and has the advantages of shorter treatment time, greater convenience to the patient, and less cost to the healthcare system compared with conventional radiotherapy.
Delirium is an exceedingly prevalent syndrome among patients with cancer, but is underrecognized and undertreated.
Patients with cervical and endometrial cancers experience fewer gastrointestinal and genitourinary adverse events and have improved quality of life when they receive intensity-modulated radiation therapy (IMRT) compared with conventional radiation therapy.
At the 2016 Palliative Care in Oncology Symposium, the message was clear and emphatic: caregivers should be viewed as both co-deliverers and co-recipients of healthcare services.
As a result of the FDA approval of the DigniCap (Dignitana) system last year, and the growing evidence that scalp cooling is effective in preventing chemotherapy-induced alopecia, the practice is steadily becoming more widespread in the United States.
Stomatitis is a dose-limiting toxicity associated with the use of mammalian target of rapamycin (mTOR) inhibitors, but new treatments can improve quality of life for patients suffering from this often debilitating condition.
Page 2 of 3
Results 11 - 20 of 26